Tokyo Japan and Cambridge, Mass. –May 24th, 2019–EdiGENE, an emerging biotechnology company developing new CRISPR based therapies for treatment of genetic disorders, announced today that it has completed its series B finance with additional 900 million-yen (approx. $8 Million) invested as the second tranche. The new participants in the Series B included new investors, Shinsei Capital Partners and Pegasus Tech Ventures.
The additional funds will be used to grow operations and expand into new therapeutic areas. With this close, the company has financed 4.6 Billion (~$40 million) to date.
EdiGENE is an emerging biotech company that develops therapeutics using its proprietary technology CRISRR-GNDM. Our people, products, and partners believe “every life deserves attention” and our mission is to develop therapeutics primarily for genetic orphan disorders that affect fewer than 200,000 people or fewer than 1 in 2,000.